The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

BACKGROUND: Cell cycle regulators have gain attention as potential targets for anticancer therapy. Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which coordinate the G1-S transition. Palbociclib is currently approved for the treatment of hormone receptor posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cretella, Daniele, Ravelli, Andrea, Fumarola, Claudia, La Monica, Silvia, Digiacomo, Graziana, Cavazzoni, Andrea, Alfieri, Roberta, Biondi, Alessandra, Generali, Daniele, Bonelli, Mara, Petronini, Pier Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872523/
https://www.ncbi.nlm.nih.gov/pubmed/29587820
http://dx.doi.org/10.1186/s13046-018-0741-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872523/
https://www.ncbi.nlm.nih.gov/pubmed/29587820
http://dx.doi.org/10.1186/s13046-018-0741-3

Ejemplares similares